Lenz Ther­a­peu­tics eyes bet­ter vi­sion than Ab­b­Vie, Ora­sis with $80M+ for three PhI­II tri­als

Lenz Ther­a­peu­tics thinks it can de­liv­er a bet­ter eye drop than Ab­b­Vie’s Vuity and Ora­sis Phar­ma­ceu­ti­cals’ CSF-1, un­der FDA re­view. And the San Diego biotech has $83.5 mil­lion to test those am­bi­tions in three Phase III tri­als.

The late-stage stud­ies are un­der­way and will read out da­ta on about 800 pa­tients to­ward the end of this year and ear­ly 2024, pres­i­dent and CEO Eef Schim­melpen­nink told End­points News on Tues­day morn­ing. The fi­nanc­ing will bankroll the com­pa­ny for at least two and a half years, he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER